Dynacure SA

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs.  Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Dynacure S.A. has filed proposed terms for a $100 million IPO. The firm is developing treatments for serious neuromuscular diseases.

News for Dynacure SA Stock (DYCU)